Clinical trials: Rabies Virus Infection
Rabies (Healthy Volunteers)
A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody
A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
- Trial name
- NCT07445815
- Testing
- Recombinant Human Rabies Virus Monoclonal Antibody Injection, Human Rabies Immunoglobulin (HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Rabies, Japanese Encephalitis
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure…
- Trial name
- NCT01662440
- Testing
- Rabies, Japanese Encephalitis
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 661 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Healthy Volunteers (Rabies Immunization)
Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year
The primary objective of the study is to demonstrate that a short intramuscular (IM) pre-exposure prophylaxis (PrEP) regimen is non-inferior to the reference IM PrEP regimen in terms of seroconversion rate.
- Trial name
- VAJ00001 (NCT03700242)
- Testing
- HDCV, PVRV
- Where
- 2 sites in Philippines
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
The primary objective of this clinical study is to assess the safety, and reactogenicity of CV7202 mRNA-rabies vaccine in healthy adults. Immunogenicity is also assessed.
- Trial name
- NCT03713086
- Testing
- Rabipur®, Rabies mRNA vaccine CV7202
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- CureVac
Rabies
Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG
A comparative,randomized (1:1)study to evaluate the safety and immunogenicity of a new chromatographically purified vero cell rabies vaccine (SPEEDA) and chromatographically purified vero cell rabies vaccine (SPEEDA)which is…
- Trial name
- NCT01137045
- Testing
- SPEEDA and TRCS SPEEDA
- Where
- 2 sites in Thailand
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Rabies
Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults
Study design: Single-blind (subject and observer-blinded), active-controlled, randomized [6:2:1:2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs. placebo + PVRV vs.
- Trial name
- NCT01228383
- Testing
- Rabies virus-specific monoclonal antibodies, human polyclonal rabies immune globulin (HRIG), Human diploid cell vaccine (HDCV)
- Where
- India
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza-like Illness, Upper Respiratory Disease
Non-specific Effects of Rabies Vaccine
Vaccines work by stimulating the body to produce a high-quality, rapid and specific immune response upon exposure to infection by a particular disease-causing microorganism - the microorganism targeted by the vaccine.
- Conditions
- Influenza-like Illness, Upper Respiratory Disease, Diarrhea, Fever
- Trial name
- NCT03656198
- Testing
- Rabivax-S, Sterile Water Injection
- Where
- Saint Kitts and Nevis
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Ross University School of Veterinary Medicine
Rabies
Immunity Persistence After Abridged Intradermal Rabies PEP
After exposure, rabies can be prevented in almost 100% of cases by the administration of sufficient and timely post-exposure prophylaxis (PEP).
- Trial name
- RESIST-3 (NCT04829630)
- Testing
- rabies vaccine
- Where
- 2 sites in Cambodia, Madagascar
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Rabies Human
To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)
To evaluate the safety and immunogenicity of lyophilized human rabies vaccine (Vero cell) developed by Hualan Biological in healthy people aged 9 to 65 years with two different immunization schedules.
- Trial name
- rabies (NCT06177249)
- Testing
- Control vaccine, Experimental vaccine
- Where
- China
- Volunteers
- 1,956 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Rabies
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)
This study was intended to explore the safety and immunogenicity of the test vaccine compared to the control vaccine. The trial consisted of two phases. Phase I used an open-ended design.
- Trial name
- NCT05969626
- Testing
- 5-dose group of test vaccine, 5-dose group of control vaccine, 4-dose A group of test vaccine
- Where
- 4 sites in China
- Volunteers
- 2,460 people, healthy volunteers welcome
- Sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Rabies
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.
- Trial name
- NCT02238756
- Testing
- CV8102, Rabipur, CV8102 + Rabipur
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CureVac
Rabies
Immunological Tolerance After Frequent Rabies Booster Vaccinations
To study immunological tolerance effect after frequent rabies booster vaccination
- Trial name
- NCT03729102
- Testing
- Blood drawn after rabies vaccine booster vaccination
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Rabies
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
This study was planned to establish the non-inferiority of Rabipur administered as simulated post exposure Zagreb schedule as compared to Essen schedule, in healthy Indian adult subjects.
- Trial name
- NCT01365494
- Testing
- Purified Chick Embryo Cell Inactivated Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies, Healthy
The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
The purpose of this study is to evaluate the safety of Freeze-dried Rabies Vaccine （MRC-5 Cell) in healthy humans aged from 10-60 years old, according to the traditional Essen methods (1-1-1-1-1) vaccination.
- Trial name
- NCT02281396
- Testing
- 2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old, 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old, 2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Rabies
Rabies Immune Plasma Booster Study
Rabies immune globulin is a product that is lifesaving to unvaccinated individuals exposed to the rabies virus. Rabies immune globulin is made from plasma from immune donors.
- Trial name
- NCT01063140
- Testing
- Rabies Vaccine (RabAvert), Rabies Vaccine (Imovax)
- Where
- 10 sites in United States
- Volunteers
- 491 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Lassa Fever
DMID 23-0015; Lassa Fever CVD 1000
This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen.
- Trial name
- NCT06546709
- Testing
- LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, LASSARAB+ aPHAD-SEat 1400rU
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wilbur Chen, MD, MS
Vaccine
Safety and Immune Response of a Rabies Vaccine With the Essen Schedule and a Two-Dose Booster
Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals.
- Trial name
- NCT07672626
- Testing
- the tested vaccine, the control vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Rabies Human, Antibody Titer
Vaccine Prevention of Rabies Adopts 4-shot Immunization Method
A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)
- Trial name
- NCT05549908
- Testing
- rabies vaccine
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Changchun Zhuoyi Biological Co., Ltd